The tumor microenvironment (TME) presents differential selective pressure (DSP) that favors
the growth of cancer cells, and monovalent therapy is often inadequate in reversing the …

Despite many endeavours for the development of new anticancer drugs, effective therapy of
solid tumours remains a challenging issue. The current cancer chemotherapies may …

Engineered bacterial therapies that target the tumor immune landscape offer a new class of
cancer immunotherapy. Salmonella enterica and Listeria monocytogenes are two species of …

Increasing evidence implicates the tumor microbiota as a factor that can influence cancer
progression. In patients with colorectal cancer (CRC), we found that pre-resection antibiotics …

The use of living bacteria either as therapeutic agents or drug carriers has shown great
potential in treating a multitude of intractable diseases. However, cells are often fragile to …

The components and hospitable properties of tumor microenvironment (TME) are associated
with tumor progression. Recently, TME modulating vectors and strategies have garnished …

Tumors use multiple mechanisms to actively exclude immune cells involved in antitumor
immunity. Strategies to overcome these exclusion signals remain limited due to an inability …

There is growing interest in the role of microorganisms in human health and disease, with
evidence showing that new types of biotherapy using engineered bacterial therapeutics …

Cancer is one of the leading causes of death in the industrialized world and represents a
tremendous social and economic burden. As conventional therapies fail to provide a …

Cancer is one of the leading causes of death worldwide and the number of cancer patients
is expected to continuously increase in the future. Traditional cancer therapies focus on …